Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-06-05 | Reverse | 1:10 |
| 2013-11-21 | Reverse | 1:50 |
| 2007-02-13 | Reverse | 1:10 |
Capricor Therapeutics is a San Diego-based biotech developing cell and exosome therapies, including CAP-1002 for Duchenne muscular dystrophy and COVID-19 cytokine storm, with ongoing clinical trials and preclinical programs.
Deramiocel, Capricor's lead allogeneic CDC therapy in late-stage trials, targets cardiac and skeletal muscle issues in Duchenne muscular dystrophy and has received FDA Orphan Drug and RMAT designations.
Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 trial for its Duchenne muscular dystrophy (DMD) therapy, deramiocel. This news led to a more than fivefold increase in the company's stock price in a single day, reversing a significant downturn experienced earlier in the year after receiving a Complete Response Letter (CRL) from the FDA.
Following positive Phase 3 trial results for its lead Duchenne muscular dystrophy therapy, Deramiocel, Capricor strategically capitalized on a significant stock surge by executing a $150 million public offering. This capital infusion is a pivotal decision aimed at funding the resubmission of its Biologics License Application (BLA) and preparing for a potential commercial launch in 2026, directly addressing previous concerns about its financial runway.
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration.
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 IONS | $43.40 | COMPARE |
 PTCT | $62.44 | COMPARE |
 EWTX | $38.55 | COMPARE |
 DYN | $16.14 | COMPARE |
 SRPT | $17.89 | COMPARE |
 ACHV | $7.10 | COMPARE |
 WVE | $3.40 | COMPARE |
 SLDB | $6.80 | COMPARE |
